Onyx Pharmaceuticals Inc (ONXX)

[Gametheory101]

I find the lack of retail investor interest in ONXX puzzling.

Nexavar should get an average of almost $50,000 per patient for liver cancer in the U.S. There are an estimated 19,000 deaths per year in the U.S., over 30,000 deaths per year in Europe, over 40,000 deaths per year in Japan, and well over 300,000 deaths per year in Asia.

ONXX has about 55 million shares outstanding and a partnership with Bayer for Nexavar. ONXX splits U.S. profits 50/50, gets a lower profit percentage from the rest of the world ex-Japan but does not share in the expenses, and will receive a royalty from Japanese sales.

With Nexavar already on the market in the U.S. and Europe for kidney cancer, doctors are writing prescriptions for Nexavar for liver cancer right now.